Sagimet Biosciences (SGMT) 3rd Annual Guggenheim Healthcare Innovation Conference summary

Strategic shift and funding

• April pivot toward acne followed a U.S. market estimate of 10–15M patients with moderate-to-severe disease; fewer than half currently receive oral antibiotics or topical treatment.

• Ascletis phase II and phase III studies showed ~20% improvement in IGA success and ~20% reductions in inflammatory and non-inflammatory lesions; FDA supported one adequately powered U.S. phase III and inclusion of ages 12–17.

• $175M raised in April to fund programs through 2028; a further $115M raised recently is expected to fund denifanstat’s phase III readout and a second oral FASN inhibitor phase II data, both expected next year.

• Funding also enables development of a topical FASN inhibitor into human testing.

Mechanism and clinical evidence

• FASN inhibition specifically targets sebum production in sebocytes and also reduces inflammation; management said it addresses two of acne’s four key drivers.

• China phase III enrolled 480 patients randomized 1:1; at week 12, IGA treatment success and inflammatory and non-inflammatory lesion scores improved significantly, with ~20% effects reported.

• Treatment effect was visible by week 2 and significant by week 4; at week 52, lesion reductions approached 80% for inflammatory and 70% for non-inflammatory lesions, while safety remained consistent with the first 12 weeks.

• Dry skin and dry eye were the only related adverse events above 5%; both were mild to moderate, with no related serious or grade 3 events reported.

U.S. phase III plans

• Phase III targets 800 patients: 450 adolescents, including 300 assigned drug and 150 placebo, plus 350 adults; 530 patients are intended to enter the open-label extension (OLE).

• First patient dosed Oct. 21; nearly half of sites were activated, enrollment was expected to take ~6 months, and primary endpoint results were targeted by end-2027.

• Smart pill-bottle caps will track openings and support adherence in the double-blind study and OLE; management expects low non-compliance in the trial.

• The 12-week placebo-controlled period is expected to support key efficacy claims; the OLE is intended to establish long-term safety, with label discussions to follow the data.